Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical Evaluation of the Revised Biological and Clinical Staging Criteria for Alzheimer Disease in China.

Neurology·2026
Same author

Sex difference in the association of antiseizure medication load with cognitive decline in older people with epilepsy: A prospective study.

Epilepsy & behavior : E&B·2026
Same author

Association of Excessive Daytime Sleepiness With Long-Term Incident Dementia: The Role of β-Amyloid and White Matter Injury.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Individual gray-white matter functional connection predicts tau spread and cognitive decline in Alzheimer's disease.

NeuroImage·2026
Same author

Disturbing dreams and dementia incidence across diverse cohort studies: A COSMIC collaboration study.

Psychiatry and clinical neurosciences·2026
Same author

Plasma phosphorylated tau 217 and neurofilament light chain on the association between depressive symptoms and cognitive decline: The Shanghai Aging Study.

Psychological medicine·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
See all related articles

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Mei Pu1,2,3, Qianhua Zhao4,5

  • 1Fudan University, Shanghai, Shanghai, China.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary
This summary is machine-generated.

Blood TRPC6 mRNA levels show promise as a new Alzheimer's disease (AD) biomarker. Lower TRPC6 mRNA levels in AD patients suggest its potential for accessible and cost-effective AD screening.

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

Area of Science:

  • Neuroscience
  • Biomarker Discovery
  • Molecular Biology

Background:

  • Current Alzheimer's disease (AD) diagnosis relies on expensive and invasive PET imaging or CSF tests for amyloid-beta (Aβ) and tau.
  • There is a critical need for accessible and cost-effective biomarkers for AD screening and diagnosis.

Purpose of the Study:

  • To investigate the diagnostic utility of blood transient receptor potential canonical 6 (TRPC6) mRNA levels as a biomarker for Alzheimer's disease (AD).
  • To assess the correlation of TRPC6 mRNA levels with Aβ deposition and brain volume in AD patients.

Main Methods:

  • 1,100 participants (366 AD patients, 734 cognitively unimpaired) were enrolled.
  • Aβ deposition assessed via PET imaging; brain volume via MRI; TRPC6 mRNA levels measured in all participants.
  • AD diagnosis confirmed by Aβ positivity on PET imaging.

Main Results:

  • Blood TRPC6 mRNA levels were significantly lower in AD patients compared to controls (p < 0.0001).
  • TRPC6 mRNA levels demonstrated high diagnostic accuracy (AUC = 0.935) for identifying AD patients.
  • TRPC6 mRNA levels correlated with Aβ deposition and brain volume, outperforming other plasma biomarkers except p-tau217.

Conclusions:

  • Blood TRPC6 mRNA levels show excellent diagnostic utility for identifying AD patients.
  • TRPC6 mRNA presents a feasible, scalable, and cost-effective blood biomarker for AD diagnosis.
  • TRPC6 mRNA could potentially serve as a standalone diagnostic index for Alzheimer's disease.